Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

NCT01580293 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

NCT01790828 ·Status: COMPLETED

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery

NCT00922597 ·Status: COMPLETED

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

NCT00629837 ·Status: COMPLETED ·Phase: PHASE1

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

NCT01184820 ·Status: COMPLETED ·Phase: PHASE1

Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis

NCT02263066 ·Status: COMPLETED

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

NCT00979238 ·Status: COMPLETED ·Phase: PHASE1

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

NCT00621673 ·Status: TERMINATED ·Phase: PHASE4

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

NCT01029340 ·Status: COMPLETED ·Phase: PHASE3

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

NCT03588299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

NCT02930317 ·Status: UNKNOWN ·Phase: PHASE3

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

NCT01810666 ·Status: COMPLETED ·Phase: PHASE4

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

NCT03603275 ·Status: TERMINATED

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

NCT03876301 ·Status: COMPLETED

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

NCT01625390 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

NCT01775618 ·Status: COMPLETED ·Phase: PHASE3

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

NCT02476942 ·Status: COMPLETED

Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A

NCT00038935 ·Status: COMPLETED ·Phase: PHASE3

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

NCT02830477 ·Status: COMPLETED

Lentiviral FVIII Gene Therapy

NCT03217032 ·Status: RECRUITING ·Phase: PHASE1

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

NCT04060836 ·Status: UNKNOWN ·Phase: PHASE1

Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

NCT02697370 ·Status: COMPLETED ·Phase: PHASE4

Learning to Live With Non-severe Haemophilia

NCT05314751 ·Status: COMPLETED

Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews

NCT03054389 ·Status: COMPLETED

Clinical and Health-related Outcome of rFVIIIFc Prophylaxis

NCT04583930 ·Status: UNKNOWN